ProCE Banner Activity

Apps in Action: Answering Your Questions About Prescription Digital Mental Health Treatment

Clinical Thought

Experts in digital therapeutics and psychiatry answer a few questions about the practical aspects of incorporating digital therapeutics into practice. 

Released: November 21, 2024

Expiration: November 20, 2025

Share

Faculty

Greg W. Mattingly

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical Inc

Disclosure

Primary Author

Greg W. Mattingly, MD

Associate Clinical Professor, Washington University
President, Midwest Research Group
President, American Professional Society of ADHD and Related Disorders
St Louis, Missouri

Greg W. Mattingly, MD: consultant/advisor/speaker: AbbVie, Acadia, Akilli, Alkermes, Angelini, Axsome, Aytu, Biogen, Boehringer Ingelheim, Cerevel, Corium, Eisai, Intra-Cellular, Ironshore, Janssen, Liva Nova, Lumos Labs, Lundbeck, Manus, Neurocrine, Noven, Otsuka, Redax, Relmada, Revibe, Roche, Sage, Sirona, Sky Therapeutics, Sunovion, Supernus, Takeda, Teva, Tris; researcher: AbbVie, Acadia, Alkermes, Akilli, Alto Therapeutics, Autobahn, Avanir, Axsome, Boehringer Ingelheim, Cingulate, Click Therapeutics, Compass, Corium, Emalex, Idorsida, Intra-Cellular, Janssen, Karuna, Lumos Labs, Medgenics, Neumora, Neurocrine, NLS-1 Pharma, Redax, Relmada, Roche, Sage, Sirtsei, Sumitomo, Sunovion, Supernus, Takeda, Teva.